PPH Legal Blog

GlaxoSmithKline, Europe’s largest drugmaker, failed to release results of diabetes pill Avandia after it was linked to potentially fatal side effects, according to the Food and Drug Administration (FDA).  The FDA claims the omissions are “serious and may be symptomatic of underlying post-marketing safety reporting failures.”  The FDA claims it was never told about the results of nine studies.  An addition eleven were not included in annual reports as well.

Avandia has been linked to a 43% increased chance of heart attack as well as an elevated risk for primary pulmonary hypertension (PPH).  Avandia was approved by the FDA in 1999 and was the world’s best-selling diabetes pill before the health risks of the drug became known.

If you have been diagnosed with Primary Pulmonary Hypertension (PPH) following the use of Avandia to control blood sugar, contact the PPH lawsuit attorneys of Williams Kherkher at 1-866-950-9000 to discuss your case and to determine your legal options.